For clinically relevant studies on melanoma progression and invasiveness, in vivo experimental systems with a human cellular microenvironment would be advantageous. We have compared tumor formation from a human cutaneous malignant melanoma cell line (BL), after injection as conventional xenografts in the mouse, or when injected into a predominantly species-specific environment of human embryonic stem cell-derived teratoma induced in the mouse (the hEST model). The resulting melanoma histology was generally analogous, both systems showing delimited densely packed areas with pleomorphic cells of malignant appearance. A specificity of the integration process into the human embryonic teratoma tissues was indicated by the melanoma exclusively being found in areas compatible with condensed mesenchyme, similar to neural crest development. Here, also enhanced neovascularization was seen within the human mesenchymal tissues facing the BL melanoma growth. Furthermore, in the hEST model an additional melanoma cell phenotype occurred, located at the border of, or infiltrating into, the surrounding human loose mesenchymal fibrous stroma. This BL population had a desmoplastic spindle-like appearance, with markers indicative of dedifferentiation and migration. The appearance of this apparently more aggressive phenotype, as well as the induction of human angiogenesis, shows specific interactions with the human embryonic microenvironment in the hEST model. In conclusion, these data provide exciting options for using the hEST model in molecular in vivo studies on differentiation, invasiveness, and malignancy of human melanoma, while analyzing species-specific reactions in vivo.
Introduction
Analysis of tumor tissue architecture, its cellular morphology, and the diagnostic use of cellular and molecular markers with empirical links to origin or malignancy, constitutes the basis for current tumor pathology. In experimental cancer research, tumor properties can be reproduced to varying extents in vitro, e.g., three-dimensional growth and matrix interaction (1) (2) (3) . However, the temporal and spatial coordination of a cellular microenvironment is for obvious reasons more difficult to mimic in vitro and can only fully be accomplished in vivo. In vivo experimentation in humans is by necessity limited and as a result, animal experimentation, such as xenografting, has been the option. Extensive information has been achieved using this approach, but the lack of species-specific interaction between tumor and stroma is still a potential limitation. Indeed, specific reservations regarding the extent of xenotransplants recapitulating development of human tissue has been recognized (4) . Although there are ample evidence for conservation of major gene expression response modes across the mammals and conserved expression patterns are often linked with specific functions, exceptions exist (5) . It is reasonable to assume that limitations in cellular interactions in xenomodels could also be implied in the numerous cases where therapies toward human tumor xenografts have been shown efficient in animal studies but less efficient or even ineffective in human clinical trials. Hence, new experimental systems where human tumors can be studied in a species-specific cellular in vivo microenvironment would be advantageous.
One such system has recently been described by Tzukerman and colleagues (6, 7) . In a human microenvironment, generated within a teratoma derived from human embryonic stem cells (hESC) in immunodeficient mice, growth of various human tumor cells (ovary, prostate, lung, breast, colorectum, neural, and skin) was supported. Intriguingly, the study included an anticancer therapy that caused complete tumor regression in a traditional xenograft model but did not eradicate the same tumor in the human teratoma microenvironment model.
We have previously made use of xenografting for assaying in vivo pluripotency of new hESC lines (8, 9) , for studies of early differentiation after hESC xenotransplantation (10) (11) (12) and links to tumor development (13, 14) . Based on these studies, we hypothesize that an optimal support of tumor growth from the hESC teratoma microenviroment is supposedly at a point when the teratomas are rich in various tissues but before limited conditions leads to substantial necrosis. Injection of a low dose of karyotypically normal hESC under the testis capsule of SCIDBeige mice leads to a benign teratoma development with mainly mouse vascularization and a diminutive formation of immature human vessels (11, 15) starting from day 20 onwards, subsequently anastomizing with the host vascular system. Such neovascularization from hESC derivates coincides with a rapid expansion of the teratoma tissues. By day 30, this represents all three germ layers, and a more organized even organoid development occurs from day 45 and onwards (10) . 7 This time scale leaves an opportunity for further observations of up to an additional 45 days after injection of tumor cells. After this, the teratoma tissue grows too large to be adequately supported by the host, with extended necrotic areas developing. Using this experimental time frame, we have observed integration with ample tumor growth support after grafting human cell lines of several origins, such as neuroblastomas, medulloblastomas, and head and neck cancers. 8 Here, we report detailed studies on the integration, growth, and differentiation of a human melanoma cell line in the hEST model. The BL cell line was derived from a lymph node metastasis of a cutaneous malignant melanoma in an adult male patient (16, 17) .
Cutaneous malignant melanoma are highly aggressive plastic tumors showing a high degree of phenotypic heterogeneity and resembling multipotent dedifferentiated cells. They are able to mimic other types of cells (18, 19) and also have a molecular signature characteristic of a plastic dedifferentiated cell type (20) . Communication between the melanoma cells and the adjacent host tissues in xeno-models has been shown to be critical for their progression, and of the utmost importance for the invasion and formation of metastases (e.g., ref. 21) . Also, several lines of evidence have shown that metastatic melanoma cells are responsive to developmental cues in an embryonic microenvironment (18, (22) (23) (24) . Such plasticity of melanomas, proven both in vitro and in xeno-environments in vivo, provides further argument for studies of human melanomas in species-specific in vivo test systems, as described here for the hEST model.
As expected from earlier studies, we found the hESC-teratoma environment highly permissive for the integration and growth of injected BL melanoma cells. In addition, we found evidence of specificity for the process of integration because BL growth was exclusively found in areas compatible with condensed mesenchyme, similar to neural crest development. Specific interactions with the surrounding embryonic species-specific microenvironment were indicated by differences in melanocytic markers. In addition, a migratory BL melanoma phenotype, not observed in the xenografts, was observed in the hEST model. Spindle-like BL melanoma cells appeared in the surrounding loose mesenchymal or fibrous stroma, subsequently showing markers indicative of dedifferentiation and migration. Also, extensive human neovascularization was found in areas of human mesenchymal tissues facing the melanoma growth.
Materials and Methods
Cells. Two hESC lines, H9 (25) and HS181 (8) , both 46XX, were cultured and verified for karyotype and markers as earlier described (26) . The BL cell line was previously derived from a lymph node metastasis of a malignant melanoma in a male patient treated at the Karolinska University Hospital (16, 17) . The BL cells were cultured in Iscove's modified Dulbecco's medium supplied with 10% fetal bovine serum and 1% Penicillin/Streptomycin, at 37jC, 6.8% CO 2 , and high humidity. The male origin of BL cells used was verified using sex chromosome specific probes and fluorescence in situ hybridization (FISH; below). All cell lines used were tested negative for Mycoplasma using PCR.
Animals and generation of hESC teratomas. The experiments were performed with permission by the Regional Committee for Animal Experimentation (Dnr N107/06). Six-to 8-wk-old SCID-Beige (C.B.-17/ GbmsTac-scid-bgDF N7; M&B) males were used in the study. They were housed and maintained at 20jC to 24jC, 50% RH, a 14 to 10 h light-dark cycle with food and water ad libitum. The hESC teratomas were generated by the injection of 10 4 hESC under the testis capsule, as previously described (10, 11) . The teratomas from the two hESC lines used, H9 and HS181, were similar in support of BL-melanoma tumor growth; thus, the data presented does not distinguish results from experiments with teratomas from H9 or HS181 cells, respectively.
Injection of BL cells. BL cells from log-phase growing cultures were trypsinized, washed, counted, and subsequently injected (10 6 cells in a 20 AL volume) either s.c. in the flank (sc; 2 mice), under the testis capsule (it; 3 mice), or into day 40 hESC teratomas induced under the testis capsule (hEST model; 4 mice). All BL-injected mice developed detectable BL tumor growth. Fourteen days later, the mice were sacrificed (cervical dislocation) and the teratoma/tumor growth removed and fixed in 4% neutral buffered paraformaldehyde overnight. The tissues were dehydrated through a graded series of alcohols to xylene, embedded in paraffin, serially sectioned into 5-Am-thick sections and stained using standard H&E.
FISH. Identification of the grafted tumor cells and hESC, respectively, was carried out by selecting opposite sex of grafted tumor cells and the hESC line used. A mixture of two Y and X chromosome-specific FISH probes (CEP XY; Vysis, Inc.) was used to distinguish between grafted cells of hESC origin (XX) and tumor origin (XY).
Briefly, slides were deparaffinized in xylene and rehydrated in a series of alcohol, followed by pretreatment with pepsin at 37jC. Genomic DNA and probe were denatured simultaneously by 5 min heating at 73jC. Hybridization was performed overnight at 42jC with a sex-specific FISH probe (CEP XY; Vysis, Inc.).
Immunocytochemistry. BL cells in culture were stained for the melanoma-associated markers HMB45, MelanA, or a combination of HMB45+MelanA+tyrosinase. Briefly, the cells were fixed for 5 to 10 min in 4% formaldehyde. Blocking was performed using 3% bovine serum albumin in PBS, primary antibodies were diluted (Table 1 ) and incubated for 1 h at room temperature. Incubation with secondary antibody was performed for 30 min at room temperature. Finally, the cells were counterstained using 4 ¶,6-diamidino-2-phenylindole (DAPI).
Immunohistochemistry. Slides with sections from teratoma/BL-tumor were deparaffinized in xylene and rehydrated in series of alcohol. Endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 for 15 min, and antigen retrieval was performed as optimized for each antibody ( Table 2 ). Blocking of unspecific binding was performed in 3% serum in PBS. Slides were incubated with primary antibody followed by incubation with secondary antibody (Table 1) . Sections were dehydrated in ethanol and xylene, and mounted with Vectamount (Vector Laboratories, Inc.).
Masson Trichrome staining for collagenous matrix. The tissue sections were deparaffinized in xylene and rehydrated through graded series of alcohol. Counterstaining was performed using hematoxylin (8 min), and sections were thereafter continuously stained in Biebrich Scarlet-Acid Fuchsin Solution, Phosphomolybdic-Phosphotungstic Acid Solution, and finally Alinin Blue Solution for 5 min each. Sections were dehydrated in ethanol and xylene and mounted with Vectamount (Vector Laboratories, Inc.).
Image analysis. Imaging was performed using a Zeiss Axiovert 200M microscope and Openlab 5.0 software. Images in Figs. 1 to 3 were adjusted for auto levels in Photoshop.
Results
Histology of BL common to xenografts and the hEST model. The predominant histology in both xenografts and the hEST model (Fig. 1A-C) was a malignant, pleomorphic, appearance of densely packed BL melanoma cells, with large irregular nuclei, distinct nucleoli, and a less prominent cytoplasm. This cellular morphology was similar to tumor cells in the original BL patient metastasis, as seen from archival-fixed H&E-stained sections from the original tumor (exemplified in Fig. 1D ).
Besides a high frequency of atypical mitotic figures (data not shown), all models showed a proliferation rate of f30% to 40% as calculated by Ki67 staining (1,000 cells counted in each section). Also, the degree of vascularization in the original metastasis and the experimental models did not apparently differ in that a similar occurrence of vessels was observed in ocular inspections of all sections (data not shown). However, a higher density of cells and lower abundance of stroma was observed in the experimental tumor models (Fig. 1A-C ) compared with the original metastasis (Fig. 1D) .
Features of BL melanoma cells in the hEST model. In the hEST model, the BL cell injection could not for practical reasons be guided into specific parts or structures of the teratoma. Therefore, the BL cells were injected randomly into the teratoma mass. In spite of this, a specificity of the integration was noticed. Using FISH analysis for human Y chromosome (red signal) and X chromosome (green signal), the BL cells were identifiable from hESC derivates (XX; double green signals). With this method BL cells were exclusively detected in areas compatible with mesenchyme. Typical areas of verified BL cell growth are illustrated in Fig. 2 , and a further example also showing the corresponding FISH results are illustrated in Fig. 3 . In four repeated experiments, melanoma cells were never detected within areas/tissues compatible with development into primitive neuroectoderm, secretory, or other epithelial structures, cartilage, etc., or in more organoid structures, such as primitive renal tissues or gut.
Albeit at a lower frequency compared with the predominant growth mode common to both models, the hEST model revealed an additional BL phenotype not present in the xenografts. This phenotype was characterized by a desmoplastic and spindle-like appearance and occurred adjacent to the areas of dense growth and within the surrounding human loose mesenchymal or fibrous stroma ( Fig. 3A and B) , as positively identified by FISH analysis (Fig. 3) . A notable human neovascularization was indicated in the surrounding stroma by staining for human CD31 (Fig. 4A) . Vascularization within areas of dense tumor growth was negative for human CD31 indicating mouse origin (data not shown).
Melanomas have been reported to be capable of vasculogenic mimicry to support their own growth and progression, i.e., by up-regulation of endothelial-associated genes such as VE-cadherin participating in the angiogenic process (27) (28) (29) . However, using FISH analysis, we failed to detect BL cells in the endothelial cells lining vessels. Instead, double signals for an X-specific probe suggested that the observed neovascularization was mainly of hESC origin (data not shown).
Using Masson Trichrome staining for collagenous matrix, an increased presence of collagenous stroma was seen along the front (Fig. 4B) , compared with the more central areas of the BL tumor, which were generally poor in stroma.
Influence of the injected melanoma BL cells on the formation of the hESC-teratoma. The wide developmental pluripotency of the hESC lines used did not seem to be affected by the injections of BL melanoma cells into the developing teratomas. Similar to our previous observations, the hESC teratomas showed a progressive chaotic formation of tissues with marker expression and morphology indicative of all three germ layers, occurring with or without injections of BL cells (data not shown). Furthermore, in line with earlier findings of benign development in teratomas from karyotypically normal hESC (11, 12) , no histological signs of malignancy in the hESC-derived tissues could be found in any of the preparations.
Cellular differentiation markers linked to malignant phenotype. S100A4 is a marker linked to migration and invasive capacity of malignant melanomas (30) . Staining using monoclonal antibodies specific for the human S100A4 subtype (31) revealed a scattered expression in all models with single cells or small clusters in the dense areas. However, in the hEST model, a specific S100A4 pattern was observed with high expression in cells in periphery of the dense areas and also within the adjacent human stroma, including both melanoma cells and fibroblasts (Fig. 4C) . This contrasted to the peripheral parts of the xenografted tumors, which showed more dispersed single S100A4+ cells. The adjacent mouse stroma did not show presence of human S100A4+ cells, as illustrated in Fig. 4D . Staining using a polyclonal antibody for the family of S100-proteins, often used in routine histopathology as a neuroectodermal indicator, revealed stained areas of varying intensity in all three models (data not shown).
HMB45 and MelanA and are markers used in the clinic (often in combination with tyrosinase) to support the diagnosis of malignant melanoma. Regarding the BL melanoma cell line, original material from the patient metastasis was diagnosed as only partly HMB45 positive (historical information from patient journal). In vitro cultured BL cells were negative for both HMB45 and MelanA when analyzed by immunohistochemistry (IHC; data not shown; ref. 17) . In contrast, after injections into sc or it locations in vivo, an extensive cytoplasmic expression of HMB45, MelanA, and tyrosinase could be detected (data not shown; illustrated for MelanA in Fig. 5A ). Interestingly, BL cells injected into the hEST model remained generally negative for all three markers, with the exception of few dispersed cells positive for MelanA (data not shown; Fig. 5B and C) .
Nodal, a marker linked to dedifferentiation and a neural crestlike phenotype, was rarely expressed in xenografted cells and then only in very few dispersed cells (data not shown). In the hEST model, Nodal-expressing cells were, almost exclusively, present focally at the border of invading fronts (Fig. 5D ). Nestin and nerve growth factor receptor (NGFR, also denoted p75) are two other markers reportedly linked to dedifferentiation of melanoma cells (32, 33) . Both Nestin and nerve growth factor receptor were generally positive in the BL melanoma cells in all models (data not shown).
A summary of the marker studies in the different models is shown in Table 1 .
Discussion
The presented findings verify the proof of concept for the hEST model as an alternative and novel in vivo platform for studies of human tumor cell lines, as previously suggested (6, 7) for several other human cell lines of different tumor origins. Importantly, however, we show the feasibility of molecular studies on in vivo tumor progression by comparing this model with conventional xenograft models (after sc or it injections) using markers linked to differentiation, malignancy, and invasiveness of melanomas.
The BL melanoma cell line used here is negative for the markers HMB45 and MelanA (this study and ref. 17) . In vivo xenografts of the BL melanoma cells showed high expression of HMB45, MelanA, and Tyrosinase, a combination of three differentiation markers commonly used for the clinical diagnosis of malignant melanoma.
When injected into the hEST model, the engrafted BL cells, however, remained negative for all three markers. Thus, the xenoenvironment resulted in the expression of a set of differentiation markers that were not induced in the species-specific embryonic environment present in the hEST model.
Furthermore, Nodal, a marker linked to dedifferentiation and neural crest cells, showed the opposite occurrence. This marker was almost exclusively found expressed in the hEST model, at the border of invading BL fronts, and was generally negative in all other tested locations. There are several possible explanations for these differences and continued studies are now needed to distinguish the effect of species-specific interactions from influence of developmental cues (embryonic environment versus adult tissues). Potentially, the findings could also be of interest in the context of using these diagnostic markers for malignant melanoma.
In the xeno-models, although showing a malignant, pleomorphic, appearance, and also expression of the HMB45, MelanA, and tyrosinase markers, the BL growth was homogeneous with no signs of invasive behavior. A second type of growth was however observed in the hEST model, with areas of BL cells apparently migrating into the surrounding human stroma. A migrating phenotype of these cells was indicated by a positive staining for the S100A4 protein, a marker for malignant melanomas linked to migration and invasive capacity (30) . This link is believed to be exerted by the ability of S100A4 to remodel the cytoskeleton or extracellular matrix via interactions with intermediate filaments such as actin. Several members of the S100 protein family also interact with p53, giving these proteins further ability to affect tumorigenesis in melanomas (23, 30, (34) (35) (36) . The exclusive finding of Nodal-expressing melanoma cells in the invading population is interesting because the embryonic morphogen Nodal has been found to be important for the invasiveness and tumorigenicity of melanomas (17) . Specific inhibition of Nodal signaling could also promote reversion of a metastatic melanoma toward a less invasive and nontumorigenic phenotype (37) . Considering this, it may be argued that the expression of genes linked to dedifferentiation, combined with the absence of markers linked to differentiation, suggests a more aggressive phenotype of the migrating BL melanoma cells in the hEST model. Thus, the hEST model allows us to compare melanoma cells in delimited dense focal areas, with melanoma cells migrating into surrounding human stroma in vivo. A second very important finding was the active human neovascularization occurring in the areas of human mesenchymal tissues facing the invasive melanoma growth in the hEST model. This finding is in line that of Tzukerman and colleagues (6) who reported extensive human neovascularization adjacent to and within growth of the A431 epidermoid carcinoma cell line, when using a similar experimental set-up. Contrary to Tzukerman and colleagues (6), we found vascularization within the tumor to be only of mouse origin. Because the development of mature human vessels in hESC teratomas is generally weak (11, 15) , the integration of injected BL melanoma cells into the hESC teratoma in our system was initially prioritized close to mouse vessels. The observed strong human angiogenic response was probably a later event, occurring after integration and initial growth of melanoma cells. Because numerous anticancer therapies aim to interact with the angiogenic potential of tumors, this gives an opportunity both for exploring molecular signal systems regulating neovascularization and for the development and testing of new and more effective antiangiogenic therapies. The observed neovascularization also further stresses the importance of species-specific systems because the angiogenic response in this case was from the hESC-derived cells, not from the mouse endothelial cells or the BL melanoma.
From earlier studies, we know that the vast majority of cells in this hESC-teratoma microenvironment are of human origin but that host cells contribute to specific microstructures in the teratoma. This is predominantly, but not solely, restricted to the endothelial cells of the vessels, a few remaining and degenerate seminiferous tubules, and the supply of host blood cells (10) . The human embryonic tissues show a remarkable degree of organization, even organoid development, and should be regarded as allogeneic in that undifferentiated hESC express not only low levels class I transplantation antigens (38) but also ABO antigens (39) . Furthermore, the differentiated hESC derivatives show increased expression of histocompatibility antigens (40) . The use of immunodefective SCID-BEIGE mutant recipients, which lack both T and B lymphocytes, as well as having a selective impairment of natural killer cell functions and macrophage defects (41) efficiently abrogates most immune recognition from the host. Thus far, we have never seen any signs of rejection in the hEST model.
The hEST model may provide a means for studies on tissue tropism of migrating cells. BL cells were injected randomly into the teratomas and therefore not intentionally guided into any specific tissue. They exclusively ended up in areas mostly compatible with condensed mesenchyme. Such areas are also compatible with neural crest development and in this respect our data resemble the results of Kulesa and colleagues (22) . In a chicken model, they found that transplanted melanoma cells were distributed along host neural-crest-cell migratory pathways. Notably, no BL growth could be observed in tissues known to be targets of metastatic lesions for melanomas, such as lung epithelium. However, this might be expected considering the long in vitro adaptation of this cell line, as well as its origin from a regional lymph node metastasis and not a visceral metastatic tumor. Ongoing experiments with unmanipulated clinical melanoma tissue may shed further light on this.
The BL cell line carries one of the common activating oncogene mutations associated with cutaneous melanoma, the NRAS Q61R mutation (41) . We have previously shown that several characteristics of the malignant phenotype of BL cells seem to be associated with oncogenic NRAS signaling (42, 43) . Knocking down the expression of NRAS Q61R by specific siRNAs led to marked effects of cellular signaling downstream of oncogenic NRAS, as well as inhibition of proliferation, induction of apoptosis, and inhibition of migration and invasion of BL cells grown in vitro. These results indicated that oncogenic NRAS is essential for the malignant behavior of human melanoma cells carrying such a mutation. This oncogene and its effectors may be promising targets for future specific therapy in melanoma. We anticipate that the hEST system will now allow us to closely analyze the effects of interference with oncogenic NRAS signaling, as well as many other molecular aspects of human tumor progression in vivo.
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